Arrowhead Pharmaceuticals, Inc. announced on February 21, 2024, the Board of Directors announced that it would increase the size of the Company's board of directors from seven to eight members and appoint Hongbo Lu, Ph.D., as an independent director of the Company, effective April 1, 2024. Dr. Lu brings over 20 years of healthcare investment experience in both public securities and private companies, including her tenure as a Managing Partner of Vivo Capital, as a Managing Partner at Lilly Asia Ventures (LAV), and as a Managing Director at OrbiMed Advisors. Additionally, Dr. Lu is the founding member of NEXTBio Capital.

Over her investment career, Dr. Lu has previously served on the boards of over 20 healthcare companies, including Turning Point Therapeutics, CrownBio, Avedro, Terns Pharmaceuticals, BlossomHill, Zenas, Createrna, Avistone, Echosens, and was extensively involved in the formation of ADARx, Ribox, Visrina, Ablaze, Elpiscience, and Ronovo. Dr. Lu received her undergraduate degree in Material Science and Engineering from Tsinghua University, China, her Ph.D. in Biological Engineering from the University of Washington, and her MBA from the University of California, Berkeley.